Summary Following EMS mutagenesis, three estramustine (EM) 
Estramustine (EM) is a chemotherapeutic agent used in the treatment of hormone-refractory, advanced prostate carcinoma (Jonsson et al., 1977; Kuss et al., 1980) . As illustrated in Figure 1 , EM is an oestradiol linked to nor-nitrogen mustard through a carbamate-ester bond, which is largely responsible for the unusual pharmacologic properties of the drug. The stability of this bond accounts for the long clinical half-life of the parent molecule (Gunnarsson et al., 1981; Gunnarsson et al., 1984) . In addition, in vitro studies revealed that EM acts independently of its constituent alkylating and estrogen moieties (Tew, 1983; Tew et al., 1983) . Specifically, EM binds noncovalently to microtubule associated proteins (MAPs) producing microtubule disassembly, stathmokinesis, and eventual cell death (Hartley-Asp, 1984 ; Stearns & Tew, 1985; Stearns & Tew, 1988; Kanje et al., 1985) . EM also binds a cytoplasmic protein which has been demonstrated in high concentrations in the ventral prostate of both rat and man (Bjork et al., 1982; Forsgren et al., 1979a) . This protein, subsequently named estramustine binding protein (EMBP) serves to localize EM in prostate tissue and binds the drug with a high affinity and high capacity (Forsgren & Bjork, 1984; Forsgren et al., 1979b) .
One of the major obstacles to cancer chemotherapy is that tumours develop resistance to drugs used for treatment; therefore, understanding the mechanisms by which this resistance is developed is important for improved clinical applications. Towards this goal, we studied the potential mechanisms by which human prostate carcinoma cell lines (DU 145) become resistant to EM. Estramustine, in common with some MDR drugs, exhibits anti-microtubule effects (Bech-Hansen et al., 1976; Beck, 1983) ; therefore, we compared EM-resistance properties with the multidrug resistance phenotype, as well as other anti-microtubule agents. Multidrug resistance is characterised by cross-resistance to structurally and functionally unrelated drugs, overexpression of plasma membrane Pglycoprotein, and increased levels of the detoxification en-
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Figure 1 Chemical structure of estramustine. Estradiol is connected to nor-nitrogen mustard through a carbamate-ester linkage.
zyme glutathione S-transferase pi (Ling & Thompson, 1974; Ling, 1975; Kartner et al., 1983; Batist et al., 1986) . Because microtubules play a major role during mitosis and EM exhibits anti-microtubule properties, we examined the drug's effect on the cell cycle of both sensitive and resistant lines. Other types of drug resistance include altered drug transport mechanisms. Using 3H-EM, we investigated the possibility that differential drug uptake and/or efflux characteristics were responsible for the development of EM resistance.
The goal of our study was three-fold: (1) Hialeah, FL) . Triplicate wells were counted for each time point and the experiment was repeated three times. Glutathione (GSH) levels and GST activity were determined through methods previously published (Griffith, 1980; Habig et al., 1974) .
Northern blot analysis of RNA from wild type and resistant lines Total cellular RNA was isolated by an acid-phenol-chloroform extraction (Chomczynski & Sacchi, 1987) Analysis of cellular uptake and release of3H-EM 3H-estramustine (2,4,4,7-3H) was provided by Pharmacia Leo Therapeutics AB (Helsingborg, Sweden). Radiochemical purity was determined by high performance liquid chromatography to be >98%.
Uptake of 3H-EM was determined by incubating cells for time periods from 0-24 h at 37°C with 1 iLCi ml-' of labelled EM in media containing 2.5 tLM cold drug. At each time point, cells were washed with cold PBS, trypsinised and an aliquot removed for cell number determination. Cells were centrifuged through silicon/mineral oil (4:1) at 13,000 g for 3 min, media and oils were carefully aspirated and cell pellets were resuspended in a hypertonic lysis buffer. Cells were transferred to scintillation vials with 5.0 ml Ecoscint A scintillation fluid and radioactivity was determined with a Beckman LS 9800 liquid scintillation counter.
Drug efflux was determined following an initial 2 h incubation of cells with 3H-EM in the conditions described above. Drug-containing media was aspirated from cells, which were then washed and refed in drug-free media. At time-points from 0 min-4 h post drug-incubation, cells were prepared as described above. All experiments were performed in triplicate and repeated at least twice.
Rate constants for drug efflux were calculated using nonlinear regression analysis.
Cell volume calculation Cell volumes were determined using an electronic particle counter equipped with a size-distribution analyser (Coulter Electronics, Inc., Hialeah, FL). Accumulated data was displayed graphically and digitally and plotted on an XY recorder. Ragweed pollen standard was used to calculate the calibration constant (K). Cell volumes (V) were calculated from the following equation:
where APC = aperture current, AMP = amplification and T is the modal threshold value determined graphically. One of the primary alterations in MDR cells is an increased expression of the MDR1 gene product, plasma membrane P-glycoprotein. Therefore, using Northern blot analysis, EMR clones were tested for increased message levels of P-glycoprotein. As seen in Figure 3 , EMR clones did not (Ling, 1974;  for review see Schibler and Cabral, 1985) , (2) mutants exhibiting tubulin subunit alterations (Cabral & Barlow, 1989 including the MDR phenotype (Batist et al., 1986; Schisselbauer et al., 1989) . Thiol-containing molecules, such as glutathione, have been shown to have a critical role in maintaining microtubule structure and organisation of the mitotic spindle during cell division (Kimura, 1973; Onefelt, 1983; Tew et al., 1985) . EM may be a substrate for GST and has been shown previously to influence GSH levels and GST activity in wild type DU 145 cells (Tew et al., 1986) . However, we found that the selection pressures producing a stable EM-resistant phenotype do not result in a significantly altered expression of GST or modified intracellular GSH. Vinblastine and taxol are known to elicit anti-microtubule effects through their direct interaction with tubulin (Bryan, 1971; Schiff et al., 1979) . The fact that the EMR clones remain sensitive to both microtubule stabilising as well as destabilising agents suggests that these cells do not express a tubulin alteration (Schiff & Horwitz, 1980 a MAP may be responsible for the observed increased sensitivity to cytochalasin B of EMR lines (Griffith & Pollard, 1978; Selden & Pollard, 1983) . Frequently, the cytotoxic consequences of anti-microtubule drugs will be manifested through effects on the mitotic spindle, since the microtubule component making up this structure demonstrates increased sensitivity to the drugs. EM has also been demonstrated to affect cells during mitosis, causing a mitotic arrest in both DU 145 and PC-3 prostate cancer lines (Hartley-Asp, 1984) . We have recently shown that EM inhibits metaphase to anaphase transition, reduced spindle pole elongation and delays onset of cytokinesis in wild type cells (Sheridan et al., 1991) . Utilising FACs in conjunction with light microscopy, we compared the effect of EM on the cell cycle of the wild type and resistant cells. Results from FACs analysis revealed that an increased percentage of wild type cells were blocked in the G2/M phase of the cell cycle in response to increasing EM concentrations. These findings are consistent with the reported stathmokinetic effects of the drug (Tew & Hartley-Asp, 1984) . In contrast, EM concentrations up to 20 JAM did not result in an increased percentage of EMR cells blocked in G2/M. Moreover, population doubling times of the EMR lines were not significantly different from wild type; although, the trend was somewhat shorter. In addition, wild type cells had nearly double the DNA content of the EMR clones, suggesting that selection favoured cells with reduced DNA content. Microscopic observations of mitotic EMR cells ( Figure 5 ) revealed that they have a smaller mitotic spindle apparatus. We hypothesise that the reduced chromosome number (unpublished observations) of the EMR clones is related to the smaller mitotic spindle, and perhaps reflects a propensity for cells with altered spindle components to survive the EM challenge. Of interest, MAPs have been shown to stimulate DNA synthesis in vitro, suggesting a role for these proteins in the regulation of DNA replication (Shioda et al., 1989) . Cellular DNA is not a target for EM Hartley-Asp, 1984) ; however, recent studies showed nuclear uptake of the drug (HartleyAsp & Kruse, 1986) . The authors report that EM binds to the nuclear protein matrix, possibly through interactions with a MAP-like protein. Thus, one may speculate that EM binding to nuclear MAPs indirectly interferes with DNA synthesis, and resistant cells have adapted through a decreased DNA content with concomitantly fewer chromosomes.
Alterations in drug transport mechanisms are correlated with the development of resistance. The possibility that EMR clones were either drug uptake or efflux mutants was examined using 3H-EM. Estramustine's ability to freely cross cellular membranes indicates little role for altered mechanisms of uptake, such as energy-dependent or carrier-mediated, in the development of resistance. Our results confirm this. The rapid incorporation of EM into wild type and EMR cells is consistent with reported patterns of EM uptake in human prostate cancer (1013L) and HeLa S3 cell lines (Kruse & Hartley-Asp, 1989 ). Similar to our findings, the authors demonstrated 50-60% EM uptake within 5 min and maximum uptake by 1 h. The maximum EM content of two of the resistant clones was only half that of the wild type line. However, the modal cellular volumes of these clones was also only 50% of the wild type. Thus, we conclude that altered drug uptake is not responsible for the development of EM resistance. Results from drug efflux studies indicate that the EMR clones do have altered patterns of EM extrusion. All three resistant clones had much greater initial efflux rate constants than wild type cells. The exact mechanisms responsible for the enhanced EM efflux from resistant cells remains to be elucidated; however, we have definitively demonstrated that P-glycoprotein is not expressed in the cells. We cannot conclude at this time that the enhanced EM efflux from the EMR cells has a role in their development of resistance. The wild type cells may have increased levels of EM binding protein or possibly sequester the drug in organelles such as vesicles. Either of these events would result in increased drug accumulation and hence decreased drug efflux. These hypotheses are currently being investigated.
The lack of cross resistance demonstrated by the EMR lines has significant therapeutic implications and can be the basis for use of EM in combination with other chemotherapeutic agents. Biochemical analysis and discovery of the unique mechanism of action of EM serves as the rationale for its use in combination with anti-microtubule agents. Using a tubulin-binding drug in addition to EM would appear to be a rational approach to enhance cytotoxicity through anti-microtubule activity. This concept is supported by in vitro studies which demonstrated that EM enhanced the effect of vinblastine on microtubule disassembly in malignant mouse and DU 145 cell lines (Mareel et al., 1988) . This pre-clinical rationale, together with the non-overlapping host toxicities of EM and vinblastine create an encouraging basis for evaluation of this combination in human diseases. An early Phase II trial escalating vinblastine to dose-limiting toxicities produced equivocal results (van Belle et al., 1988) . We have initiated a Phase II study where EM doses are escalated, while maintaining vinblastine at non-toxic levels. From the pre-clinical data, there is no reason to assume that resistance to one agent will be accompanied by collateral resistance to the other.
